BMEA (Biomea Fusion) 50-Day SMA: $1.35 (As of Jul. 12, 2026)


BMEA Biomea Fusion Inc BMEA
30 GF Score
Price $1.32
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion 50-Day SMA?

Biomea Fusion BMEA 30 50-Day SMA is $1.35 as of Jul. 12, 2026. GuruFocus rates BMEA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2026-07-12), Biomea Fusion's 50-Day SMA is $1.35. It's 20-Day SMA is $1.29 and 200-Day SMA is $1.42.

Biomea Fusion  (NAS:BMEA) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.

Biomea Fusion 50-Day SMA Related Terms

BMEA vs ANIX, PMN, ATRA: 50-Day SMA Comparison

For the Biotechnology subindustry, Biomea Fusion's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion 50-Day SMA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's 50-Day SMA falls into.


BMEA
30GF Score
Biomea Fusion Inc BMEA
50-Day SMA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion  (NAS:BMEA) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 50-Day SMA →
What does a 50-Day SMA of $1.35 mean?
Biomea Fusion (BMEA) has a 50-Day SMA of $1.35 as of Jul. 12, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Biomea Fusion and its competitors.
Is Biomea Fusion's 50-Day SMA too high?
Biomea Fusion's current 50-Day SMA is $1.35. Overall, Biomea Fusion has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's 50-Day SMA compare to ANIX and PMN?
Biomea Fusion's 50-Day SMA of $1.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Biomea Fusion and its competitors. Biomea Fusion's current 50-Day SMA is $1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current 50-Day SMA of $1.35. The current 50-Day SMA is $1.35. Biomea Fusion's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current 50-Day SMA is $1.35 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
30GF Score

Get the complete analysis for BMEA

50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price